Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

22%

5 trials in Phase 3/4

Results Transparency

24%

4 of 17 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1
15(65.2%)
Phase 3
5(21.7%)
Phase 2
3(13.0%)
23Total
Phase 1(15)
Phase 3(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT05648500Phase 3Active Not Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Role: lead

NCT06475742Phase 3Enrolling By Invitation

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Role: lead

NCT04957719Phase 3Enrolling By Invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Role: lead

NCT07201129Phase 3Recruiting

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Role: lead

NCT05672576Phase 3Active Not Recruiting

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Role: lead

NCT07301723Phase 1Completed

A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants

Role: lead

NCT07133191Phase 1Completed

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

Role: lead

NCT02472795Phase 1Completed

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Role: lead

NCT03742037Phase 2Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Role: lead

NCT02479204Phase 1Terminated

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Role: lead

NCT04255277Phase 1Completed

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Role: lead

NCT04819464Phase 1Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Role: lead

NCT02914223Phase 1Completed

A Study to Evaluate Cenerimod in Healthy Male Subjects

Role: lead

NCT05004311Phase 1Completed

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Role: lead

NCT04052360Phase 1Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Role: lead

NCT03487445Phase 2Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Role: lead

NCT03384966Phase 2Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Role: lead

NCT04406896Phase 1Completed

The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

Role: lead

NCT04557280Phase 1Completed

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Role: lead

NCT03814200Phase 1Completed

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Role: lead